INmune Bio Inc. (INMB) Earnings Call Transcripts

INmune Bio Inc.'s Latest Earnings Call - March 30, 2026

In the fourth quarter and full year of 2025, INmune Bio Inc. reported a net loss of approximately $45.9 million, an increase from $42.1 million in 2024. The company highlighted significant advancements in its CORDStrom program for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and the completion of its MINDFuL Alzheimer's trial, although the latter did not meet its primary endpoint. Management remains optimistic about 2026, with plans to file for regulatory approvals in the U.K., EU, and U.S. for CORDStrom, while also preparing for a Phase III trial for XPro in Alzheimer's disease.

Reported metrics

Guidance from management

Management is focused on advancing CORDStrom towards marketing approval and securing regulatory clarity for XPro. They expect to file the MAA in the U.K. by mid-summer 2026 and aim for feedback from regulatory agencies in 2027.

What management said

Thanks, CJ. Before I hand the call to Cory to go through our financial results, I want to emphasize from a capital perspective, we remain committed to capital efficiency. Our strategy is built on hitting clear data-driven milestones that allow us to maximize shareholder value while minimizing unnecessary burn. We're focused on maintaining the lean execution-oriented culture that has brought us to this stage. With tha...

So what they will ask is for a confirmation that we will only supply drug into the U.S. from U.S. tested donors. But in point of fact, we're making the master cell batch now. So we will have products that have been made from U.S. tested donors before we submit the BLA.

What analysts pressed on

Analysts expressed concerns regarding the failure of the MINDFuL trial to meet its primary endpoint and the implications for XPro's future. There are also questions about the adequacy of the cash position to support ongoing operations and development efforts.

Main topics on the call

• CORDStrom Regulatory Progress — Management is preparing to file the Marketing Authorization Application (MAA) in the U.K. by mid-summer 2026, with plans for subsequent filings in the EU and U.S. CEO David Moss stated, "we remain on track to file the MA...
• Alzheimer's MINDFuL Trial Results — The MINDFuL trial did not meet its primary endpoint, which raised concerns among analysts. However, management emphasized that the totality of the data supports the potential of XPro, stating, "the totality of XPro data ...
• Financial Performance — Net loss increased to $45.9 million in 2025, while R&D expenses decreased to $20.7 million from $33.2 million in 2024. CFO Cory Ellspermann noted, "the decrease [in R&D] was due to incurring lower expenses in connection ...
• XPro Phase III Preparation — Management is preparing for a Phase III trial for XPro, having aligned with the FDA on the development path. CJ Barnum mentioned, "we are now moving forward on several fronts" regarding the trial's initiation.

Read the full INmune Bio Inc. transcript (March 30, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 42 INmune Bio Inc. earnings call transcripts on record, spanning March 11, 2020 to August 6, 2026. Based on this history, INmune Bio Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

INMB

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

42

First call

March 11, 2020

Most recent

August 6, 2026

Reporting cadence

quarterly